Pricey gene therapies expected to ‘dominate’ talk at J.P. Morgan conference

If you ’re a biotech industry executive or investor, chances are you’re in San Francisco this week for the annual J.P. Morgan healthcare conference. And you can expect to hear plenty of lively discussion about gene therapies, a new class of drugs that carries both promise and perils for the biotech ind ustry. Gene therapies are intended to modify a person’s DNA — specifically, by inserting healthy genes into cells to replace faulty or missing ones. This approach, though far from foolproof,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news